Evidence map›Paper›PMID 31738183›Full record

ArticleThe Journal of clinical investigation2020

BubR1 allelic effects drive phenotypic heterogeneity in mosaic-variegated aneuploidy progeria syndrome.

Cynthia J Sieben, Karthik B Jeganathan, Grace G Nelson, Ines Sturmlechner, Cheng Zhang, Willemijn H van Deursen, Bjorn Bakker, Floris Foijer, Hu Li, Darren J Baker and 1 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. [Progress in the Study of Spindle Assembly Checkpoint in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Cynthia J SiebenDepartments of Biochemistry and Molecular Biology.
Karthik B JeganathanPediatric and Adolescent Medicine, and.
Grace G NelsonPediatric and Adolescent Medicine, and.
Ines SturmlechnerPediatric and Adolescent Medicine, and.
Cheng ZhangMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Willemijn H van DeursenPediatric and Adolescent Medicine, and.
Bjorn BakkerEuropean Research Institute for the Biology of Aging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Floris FoijerEuropean Research Institute for the Biology of Aging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Hu LiMolecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Darren J BakerDepartments of Biochemistry and Molecular Biology.
Jan M van DeursenDepartments of Biochemistry and Molecular Biology.
Mayo Clinic · USUniversity Medical Center Groningen · NL

Funding

BUBRI in Normal and Neoplastic GrowthR01CA096985 · NCI · MAYO CLINIC ROCHESTER · PI BAKER, DARREN · 2002 to 2022
$6.2M
NCI NIH HHS R01 CA096985
6 · The paper itself

Abstract

Mosaic-variegated aneuploidy (MVA) syndrome is a rare childhood disorder characterized by biallelic BUBR1, CEP57, or TRIP13 aberrations; increased chromosome missegregation; and a broad spectrum of clinical features, including various cancers, congenital defects, and progeroid pathologies. To investigate the mechanisms underlying this disorder and its phenotypic heterogeneity, we mimicked the BUBR1L1012P mutation in mice (BubR1L1002P) and combined it with 2 other MVA variants, BUBR1X753 and BUBR1H, generating a truncated protein and low amounts of wild-type protein, respectively. Whereas BubR1X753/L1002P and BubR1H/X753 mice died prematurely, BubR1H/L1002P mice were viable and exhibited many MVA features, including cancer predisposition and various progeroid phenotypes, such as short lifespan, dwarfism, lipodystrophy, sarcopenia, and low cardiac stress tolerance. Strikingly, although these mice had a reduction in total BUBR1 and spectrum of MVA phenotypes similar to that of BubR1H/H mice, several progeroid pathologies were attenuated in severity, which in skeletal muscle coincided with reduced senescence-associated secretory phenotype complexity. Additionally, mice carrying monoallelic BubR1 mutations were prone to select MVA-related pathologies later in life, with predisposition to sarcopenia correlating with mTORC1 hyperactivity. Together, these data demonstrate that BUBR1 allelic effects beyond protein level and aneuploidy contribute to disease heterogeneity in both MVA patients and heterozygous carriers of MVA mutations.

Indexed as

AllelesAgingAnimalsCell Cycle ProteinsChromosome DisordersLung NeoplasmsMiceMice, Inbred C57BLMitosisMosaicismMutationPhenotypeProgeriaProtein Serine-Threonine KinasesBub1b protein, mouseCell Cycle ProteinsProtein Serine-Threonine KinasesAgingCancerCellular senescenceGenetic diseasesOncology

Identifiers

PMID31738183
PMCPMC6934189
OpenAlexW2984066841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.